

ONCODESIGN announces its 2022 financial agenda



Paris and Dijon (France), January 5, 2022 at 6:00pm CET – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group providing the pharmaceutical industry with support finding new therapeutic molecules for fighting various forms of cancer and other serious illnesses with no known effective treatment, today announces its 2022 financial agenda.

Events	Dates*
2021 Full-Year Revenue	January 27, 2022
2021 Full-Year Results	April 7, 2022
Annual General Meeting 2022	June 29, 2022
2022 Half-Year Revenue	July 21, 2022
2022 Half-Year Results	September 15, 2022

**Information subject to change.*

About ONCODESIGN: www.oncodesign.com

Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 800 clients, including the world's largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over \$65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 233 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA. www.oncodesign.com



oncodesign.com

contacts



Oncodesign

Chairman and CEO
Philippe Genne
Tel.: +33 (0)380 788 260
investisseurs@oncodesign.com

NewCap

Investor Relations
Mathilde Bohin
Tel.: +33 (0)144 719 495
oncodesign@newcap.eu

NewCap

Media Relations
Arthur Rouillé
Tel.: +33 (0)144 710 015
oncodesign@newcap.eu

Disclaimer

This press release contains certain forward - looking statements and estimates concerning the Company's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the Company's control. Consequently, the actual results, financial condition, performances and/or achievements of the Company or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company undertakes no

obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.